Core Insights - Devonian Health Group Inc. announced additional preclinical results from its STAM mouse model study, highlighting the anti-MASH, anti-inflammatory, and anti-fibrotic effects of Thykamine™ in liver conditions [1] Group 1: Study Results - The STAM mouse model study showed that Thykamine™ significantly reduced liver disease progression, inflammation, and fibrosis at doses of 0.5 mg/kg, 5.0 mg/kg, and 50.0 mg/kg over three weeks [1] - Gene expression analysis indicated a marked down-regulation of multiple genes central to MASH pathophysiology, with reductions approaching or exceeding 80-90% compared to placebo [1] - Thykamine™ treatment significantly modulated fibrosis-related genes such as CCN1, CCN2, COL1A1, and inflammation-related genes including CCL2 and IFNG, demonstrating a dose-dependent response [1] Group 2: Market Potential - The global MASH treatment market was valued at $7.87 billion in 2024 and is projected to reach $31.76 billion by 2033, growing at a 17.7% CAGR from 2025 to 2033 [1] - Nonalcoholic fatty liver disease (NAFLD), which progresses to MASH, has a worldwide prevalence of 20-30%, indicating a significant market opportunity for treatments targeting this condition [1] Group 3: Company Overview - Devonian Health Group Inc. is a clinical stage pharmaceutical company focused on developing drugs for autoimmune fibroinflammatory conditions, leveraging over 15 years of research [2] - The company is also involved in developing high-value cosmeceutical products and operates a commercialization subsidiary, Altius Healthcare LP, for selling prescription pharmaceutical products in Canada [2] - Devonian is publicly traded on the TSX Venture Exchange (TSXV: GSD) and OTCQB (OTCQB: DVHGF) [2]